A drug to assist in the rehabilitation of the brain to ease the effects of Autism would almost be the ‘holy grail’ of neurological clinical achievements, particularly concerning children.
From personal experience I would have paid anything to assist in the therapy of my son had it been clinically proven to be successful.
Given the sheer numbers of diagnosis of autism per year, in Australia alone, and the impact that presents on the health systems of similar countries to assist those individuals throughout their lives, any successful medication would be championed by their governments.
I think it would be hard to put a figure on the share price if NNZ-2591 were successful in treating or helping to manage autism spectrum disorders.
Good Luck to all holders.
NEU Price at posting:
$2.10 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)